Overview

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
To assess the safety, tolerability and efficacy of a single dose of OTX-CSI, a sustained release cyclosporine drug product, in subjects with dry eye disease.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ocular Therapeutix, Inc.